“Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM), a neurotech company focused on neurological wellness, today announced that the Company has entered into an agreement with HealthTech Connex, Inc. (“HTC”) to develop and manage neuroplasticity clinics in Canada.
“We are excited to announce this strategic alliance with HealthTech Connex and look forward to establishing our commercial infrastructure in Canada,” said CEO Philippe Deschamps. “This new agreement with HTC will result in the formation of a new operating entity called Heuro Canada and is the first step towards our shared goal of giving hope to people with Traumatic Brain Injury by ensuring that our novel therapy will be accessible to Canadians once cleared by the regulatory authorities.” … Both the Portable Neuromodulation Stimulator (PoNS™) device and the NeuroCatch™ Platform are currently investigational devices, not for sale in Canada or the US .. Both technologies will be used in Heuro Canada neuroplasticity clinics only if and when those technologies are cleared for use in Canada by Health Canada. Subject to the foregoing, Heuro Canada is anticipated to be operational in the fourth quarter of 2018.”
News in Context:
- Transcranial Direct Current Stimulation shows early promise to ameliorate depression, especially if combined with other therapies and dosage optimized
- Eight research teams working with DARPA to discover best ways to activate neuroplasticity and accelerate learning
- The leading-edge in brain stimulation and neuromodulation: Key Neurotech Patent #36
- Neuropsychologist Amy Serin, Co-Founder of Brainnovations Winner The Touchpoint Solution, would like to see everyone avoid the detrimental effects of an overactive stress response